AUSTIN CLARK: Open Payments
NPI 1336872464 · OMAHA, NE. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$754 in 22 payments from 12 companies in 2025. Trend: 2023 $0 · 2024 $65 · 2025 $754
Food & beverage: $754
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 6 | $154 |
| Axsome Therapeutics, Inc. | 1 | $120 |
| ACADIA Pharmaceuticals Inc | 1 | $111 |
| PFIZER INC. | 1 | $62 |
| Vanda Pharmaceuticals Inc. | 2 | $60 |
| ARGENX US, INC. | 2 | $55 |
| Teva Pharmaceuticals USA, Inc. | 3 | $51 |
| Amneal Pharmaceuticals LLC | 2 | $39 |
| TG Therapeutics, Inc. | 1 | $30 |
| Genentech USA, Inc. | 1 | $28 |
Products named: Symbravo, NUPLAZID, QULIPTA, NURTEC ODT, PONVORY, AUSTEDO XR, CREXONT, VYALEV.
Industry payments across NE — which companies pay providers there.
